Description
PGMS: Pyruvate & Glutamate & Malate & Succinate.
MitoPathway control: CI&II
2-oxoglutarate is produced through the citric acid cycle from citrate by isocitrate dehydrogenase, from oxaloacetate and glutamate by the transaminase, and from glutamate by the glutamate dehydrogenase. If the 2-oxoglutarate carrier does not outcompete these sources of 2-oxoglutarate, then the TCA cycle operates in full circle with external pyruvate&malate&glutamate&succinate
Abbreviation: PGMS
Reference: Gnaiger 2014 MitoPathways - Chapter 5.6
MitoPedia O2k and high-resolution respirometry: "SUIT state" is not in the list (O2k hardware, DatLab, Oroboros QM, O2k-Open Support, O2k-Respirometry, O2k-FluoRespirometry) of allowed values for the "MitoPedia O2k and high-resolution respirometry" property.
SUIT state"SUIT state" is not in the list (O2k hardware, DatLab, Oroboros QM, O2k-Open Support, O2k-Respirometry, O2k-FluoRespirometry) of allowed values for the "MitoPedia O2k and high-resolution respirometry" property.
PGMS(L)
PGMS(P)
PGMS(E)
Discussion
Recent studies showed that CII- and CI&II-linked OXPHOS capacity is inhibited by 2 mM malate concentrations as applied in most SUIT protocols. This inhibition is less pronounced at 0.5 mM malate